Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Colorectal Cancer or Pancreatic Cancer
Completed · Phase 1/Phase 2
Conditions studied: Colorectal Cancer, Pancreatic Cancer
In brief
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by monoclonal antibody therapy used to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiolabeled monoclonal antibody plus peripheral stem cell transplantation in treating patients who have metastatic or recurrent colorectal cancer or pancreatic cancer that has not responded to previous treatment.
Key facts
- Study ID
- NCT00004087
- Run by
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
- People needed
- 15
- Starts
- 1997-03-01
- Last updated by the study team
- 2011-06-22
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Garden State Cancer Center — Belleville, New Jersey, United States
- St. Joseph's Hospital and Medical Center — Paterson, New Jersey, United States
- University of Pennsylvania Cancer Center — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.